Why is SLS stock soaring over 220% on Tuesday?

Sellas Life Sciences (SLS) stock surged 220% after reporting positive late-stage trial results for its cancer vaccine, GPS, which reduced death risk by 41% and extended median survival to 24 months in AML patients. The company plans to discuss an accelerated FDA approval pathway. SLS reported a net loss of $10.1 million in Q2. Trading was halted due to volatility.

Original reporting
Published Nov 17, 2026, 2:59 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 9:44 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMarket movers
Primary signal
$SLS
Bullish
high confidence
Mentioned
$SLS
Relevance
9/10
AlphAI data visualization · based on invezz.com
Decision brief

The 30-second read

$SLSBullishHigh
01

Why it matters

The trial results provide a clear catalyst that could accelerate FDA discussions and a 2027 BLA filing, potentially unlocking significant valuation uplift.

02

Market read

The unprecedented 220% intraday surge underscores the market's reaction to breakthrough data in a high‑unmet‑need cancer area.

03

What to watch

Future BLA filing timing, manufacturing scale‑up costs, and competition from other AML therapies could temper upside.

Relevance 9/10Novelty 9/10Timing: pre‑market today

Background

Sellas Life Sciences (SLS) is a clinical‑stage biotech focused on leukemia immunotherapies. The company has no revenue and reported a net loss of $10.1 M for the quarter.

Company-level read

Ticker impact

$SLSBullishHigh confidence
Context

Sellas Life Sciences reported positive Phase 3 trial results for its GPS vaccine, driving a 220% stock surge.

Expected impact

upward pressure as investors price in the survival benefit and potential FDA pathway.

Evidence & confidence

The trial shows a 41% mortality reduction and a median OS gain of 9.3 months, a material clinical milestone for a biotech.

Market effects

Strengthens the AML‑focused biotech niche and may lift peer companies developing immunotherapies.

Positive for US biotech sector; limited broader market effect.

Highlights the potential of cancer vaccines, could attract global investor interest.

Counterpoint

The data are from a single trial; regulatory approval is not guaranteed and the stock may be overbought after a 220% jump.

Key entities

  • Angelos Stergiou

    CEO of Sellas who commented on the trial milestone.

Related articles

$NVDAMedAI 8/10

Futures Rise As Huang-less Nvidia Beats And Raises, Gold Crashes Below $3,800

US futures rise as Nvidia (NVDA) reports strong earnings and raises guidance, boosting AI-related stocks. Gold drops below $3,800 after Fed Governor Waller's comments. Nvidia's Q4 revenue guidance is $130B vs. estimates of $125B. Premarket movers include TSLA, GOOGL, AMZN, AAPL, META, AVGO, CRWV, AAOI, BLSH, DLB, LOW, SLS, TTWO, TNDM. Fed policy and economic data releases are in focus.

$SLSHighAI 9/10

SLS Joins MRNA And ANL In Biotech’s Top 3 This Year — Here’s How A Late-2025 Bet Could Grow 10x From Here

Sellas Life Sciences (SLS) reported positive Phase 3 trial results for its cancer vaccine, Galinpepimut-S (GPS), showing a 24-month median survival vs. 14.7 months in the control group. The company plans to meet with the FDA and aims to file for approval in early 2027. SLS also announced a $150M share offering to fund further development. Analysts and investors reacted positively, with some noting potential for expedited approval and broader applications.

$SLSHighAI 9/10

SLS Joins MRNA And ANL In Biotech’s Top 3 Winners This Year — Can Sellas Deliver Another Double From Here?

Sellas Life Sciences (SLS) stock surged 156% to $19.15 after positive Phase 3 trial results for its leukemia vaccine, Galinpepimut-S. The trial showed a 41% reduction in death risk, with median survival of 24 months vs. 14.7 months in the control group. Maxim Group raised its price target to $40, citing significant upside potential. SLS is planning a $150M share offering to fund further development.

$SLSMedAI 8/10

SELLAS shares jump 157% after company says its leukemia

SELLAS Life Sciences (SLS) shares surged 157% after reporting positive Phase 3 trial results for its leukemia vaccine, galinpepimut-S, showing a 41% reduction in death risk. The stock closed at $19.17, valuing the company at $3.9B. However, after launching a $150M stock offering, shares dropped 10-13% in after-hours trading. The trial enrolled 126 patients, with median survival of 24.0 months vs. 14.7 months for existing treatments. The company plans to file for regulatory approval in 2027.